June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Vitelliform maculopathy: Natural History and Disease Progression
Author Affiliations & Notes
  • Parisa Emami-naeini
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Gary W Abrams
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Footnotes
    Commercial Relationships Parisa Emami-naeini, None; Gary Abrams, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3844. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Parisa Emami-naeini, Gary W Abrams; Vitelliform maculopathy: Natural History and Disease Progression. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3844. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To describe the natural course of vitelliform maculopathy and factors predicting final visual outcome


In this retrospective study we reviewed charts of all consecutive patients with vitelliform maculopathy who presented to Kresge Eye Institute between January 2008 and May 2014. Demographics, clinical characteristics and imaging were reviewed. Patients who had geographic atrophy on presentation or had follow-up of less than 6 months were excluded from the study.


A total of 10 eyes (5 patients) were included. Four patients (80%) were female. Mean age at presentation was 80.4± 6.6 years (range: 67-86). Mean follow up was 45.2 months (range: 14-70). Disease was bilateral in all of the patients. Best-corrected visual acuity (BCVA) deteriorated significantly (logMAR BCVA of 0.234± 0.1 at baseline vs. 0.626± 0.21 at last follow-up visit; p = 0.001). Central macular thickness did not change significantly (p=0.6). Over the follow-up course, inner segment/outer segment (IS/OS) interface disrupted in 4 eyes (40%). Five eyes (50%) developed geographic atrophy after mean of 46.8± 14.2 months. Linear regression model was used to determine factors predicting decrease in BCVA. This model determined IS/OS integrity as the only significant factor (p=0.03). None of the patients developed choroidal neovascularization.


Vitelliform maculopathy is a variant of age related macular degeneration that commonly results in geographic atrophy. None of our patients developed choroidal neovascularization. Vision loss is secondary to loss of IS/OS interface integrity.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.